指数修订“提纯”,打造“纯度”100%的创新药投资标的

中国网财经
01 Jul

近期,创新药相关指数集体走强,其中恒生港股通创新药指数以年内超60%的亮眼涨幅,成为市场关注的焦点。近年来,我国创新药取得了显著的发展成果,吸引海外药企频频出手采购,标志着我国新一批优势产业的强势崛起。6月30日,恒生港股通创新药指数宣布修订编制方案,明确剔除CXO公司(Contract X Organization,医药合同外包服务组织),成为首批在编制方案中明确剔除CXO,聚焦创新药的指数。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10